TY - JOUR
T1 - Recipient intramuscular administration of naked plasmid TGF-β1 attenuates lung graft reperfusion injury
AU - Daddi, Niccolò
AU - Kanaan, Samer A.
AU - Suda, Takashi
AU - Tagawa, Tsutomu
AU - D'Ovidio, Franco
AU - Grapperhaus, Kathleen
AU - Kozower, Benjamin D.
AU - Ritter, Jon H.
AU - Mohanakumar, T.
AU - Patterson, G. Alexander
N1 - Funding Information:
This work is supported by National Institutes of Health Grants RO1 HL-41281 (G.A.P.) and R01 HL56643 (T.M.). S.A.K. is supported by individual NRSA-NIH Grant 1F32HL68401-01.
PY - 2003/12
Y1 - 2003/12
N2 - Background: Gene therapy may be an effective strategy for modulating lung graft ischemia-reperfusion injury. We investigated whether recipient intramuscular (IM) naked plasmid gene transfer of transforming growth factor β1-active (TGF-β1-active) ameliorates lung graft ischemia-reperfusion injury. Methods: Preliminary studies in F344 rats demonstrated that gastrocnemius muscle transfection of TGF-β1-active produced muscle and plasma protein expression at 24 and 48 hours after transfection. Recipients (n = 8) received IM injection of naked plasmid-encoding chloramphenicol acetyl transferase (CAT), TGF-β1-latent or TGF-β1-active, respectively, at 24 or at 48 hours before left lung transplantation. We did not treat the control group before transplantation (18-hour cold ischemia). Donor lungs were flushed with low-potassium dextran-1% glucose and stored for 18 hours at 4°C. All groups were killed at 24 hours after transplantation. Immediately before killing the animals, we clamped the contralateral right hilum and assessed graft function. We measured wet-to-dry ratio (W/D), myeloperoxidase, pro-inflammatory cytokines (interleukin 1 [IL-1], tumor necrosis factor α [TNF-α], interferon-γ [INF-γ], and IL-2) and performed immunohistochemistry. Results: Arterial oxygenation was greatest in the recipient group transfected with TGF-β1-active at 24 hours before transplantation compared with CAT, TGF-β1-latent, and 18-hour cold ischemia groups (p < 0.01). The W/D ratio and myeloperoxidase decreased in both 24- and 48-hour groups, with TGF-β1-active compared with CAT, and 18-hour cold ischemia groups (W/D, p < 0.02 and p < 0.004, respectively; myeloperoxidase, p < 0.05 and p < 0.01, respectively). All pro-inflammatory cytokines decreased in the 24-hour TGF-β1-active group compared with CAT, TGF-β1-latent, 18-hour and 1-hour cold ischemia, and non-treated lung groups (IL-1β, p < 0.03; TNF-α, p < 0.02; IFN-γ, p < 0.001; IL-2, p < 0.0001). In 24- and 48-hour groups with TGF-β1-active, immunohistochemistry showed marked staining of Type I and Type II alveolar cells and of macrophages from the apical to the caudal sections of the lung grafts. Conclusions: Recipient IM administration of naked plasmid encoding TGF-β1-active before transplantation ameliorates lung isograft reperfusion injury after prolonged ischemia.
AB - Background: Gene therapy may be an effective strategy for modulating lung graft ischemia-reperfusion injury. We investigated whether recipient intramuscular (IM) naked plasmid gene transfer of transforming growth factor β1-active (TGF-β1-active) ameliorates lung graft ischemia-reperfusion injury. Methods: Preliminary studies in F344 rats demonstrated that gastrocnemius muscle transfection of TGF-β1-active produced muscle and plasma protein expression at 24 and 48 hours after transfection. Recipients (n = 8) received IM injection of naked plasmid-encoding chloramphenicol acetyl transferase (CAT), TGF-β1-latent or TGF-β1-active, respectively, at 24 or at 48 hours before left lung transplantation. We did not treat the control group before transplantation (18-hour cold ischemia). Donor lungs were flushed with low-potassium dextran-1% glucose and stored for 18 hours at 4°C. All groups were killed at 24 hours after transplantation. Immediately before killing the animals, we clamped the contralateral right hilum and assessed graft function. We measured wet-to-dry ratio (W/D), myeloperoxidase, pro-inflammatory cytokines (interleukin 1 [IL-1], tumor necrosis factor α [TNF-α], interferon-γ [INF-γ], and IL-2) and performed immunohistochemistry. Results: Arterial oxygenation was greatest in the recipient group transfected with TGF-β1-active at 24 hours before transplantation compared with CAT, TGF-β1-latent, and 18-hour cold ischemia groups (p < 0.01). The W/D ratio and myeloperoxidase decreased in both 24- and 48-hour groups, with TGF-β1-active compared with CAT, and 18-hour cold ischemia groups (W/D, p < 0.02 and p < 0.004, respectively; myeloperoxidase, p < 0.05 and p < 0.01, respectively). All pro-inflammatory cytokines decreased in the 24-hour TGF-β1-active group compared with CAT, TGF-β1-latent, 18-hour and 1-hour cold ischemia, and non-treated lung groups (IL-1β, p < 0.03; TNF-α, p < 0.02; IFN-γ, p < 0.001; IL-2, p < 0.0001). In 24- and 48-hour groups with TGF-β1-active, immunohistochemistry showed marked staining of Type I and Type II alveolar cells and of macrophages from the apical to the caudal sections of the lung grafts. Conclusions: Recipient IM administration of naked plasmid encoding TGF-β1-active before transplantation ameliorates lung isograft reperfusion injury after prolonged ischemia.
UR - http://www.scopus.com/inward/record.url?scp=10744226504&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2003.09.011
DO - 10.1016/j.healun.2003.09.011
M3 - Article
C2 - 14672747
AN - SCOPUS:10744226504
SN - 1053-2498
VL - 22
SP - 1323
EP - 1334
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
IS - 12
ER -